Yescarta denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for yescarta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Yescarta: Prior Authorization Required

UHC requires prior authorization for Yescarta (axicabtagene ciloleucel) before it will authorize and reimburse this CAR-T cell therapy. Because Yescarta requires specialized administration at a certified treatment center and involves a complex manufacturing process (the patient's own cells are collected, sent to a manufacturing facility, and returned), prior authorization must be in place before leukapheresis (cell collection) begins — not just before infusion. A "prior-auth-required" denial at the claim stage typically means authorization was not obtained in advance, was obtained too late in the process, or the authorization that was obtained did not match the final claim details.

## Why This Is Appealable

If authorization was not obtained due to a provider administrative oversight, a retroactive authorization request can sometimes be approved, particularly when the clinical criteria are clearly met and the urgency of the oncology situation is documented. If the PA was denied on clinical grounds, the full internal and external appeal process applies. Given the complexity and clinical stakes of CAR-T therapy, UHC typically assigns a dedicated case manager to Yescarta cases — request that assignment immediately.

## Federal Appeal Framework

• Internal appeal: File under ACA §2719 / ERISA §503 within the timeframe on the denial notice. Expedited internal appeal (72-hour decision) is appropriate and recommended for active oncology cases.
• Peer-to-peer review: Request a peer-to-peer call between your oncologist and UHC's oncology medical director before or alongside the internal appeal. This is often the fastest resolution path for CAR-T PA disputes.
• External review: If the internal appeal is denied, request IRO review within the four-month external review window. Expedited external review is available.

## Documentation to Collect

1. Diagnosis and staging — pathology, imaging, flow cytometry, and molecular testing confirming the specific diagnosis and disease classification required by UHC's policy. 2. Prior-treatment history — a complete chronological list of all prior regimens with dates, responses, and reasons for discontinuation. The number of prior lines must align with the FDA prescribing label requirements — verify against the current label. 3. Performance status and eligibility assessment — ECOG or Karnofsky score, organ function labs, and any other eligibility parameters documented in the chart. 4. Treatment center certification — documentation that the administering center holds the required CAR-T certification (REMS program compliance). 5. Prescriber medical necessity letter — addressing each criterion in UHC's Yescarta PA policy point-by-point, with specific chart citations and dates. 6. UHC's PA criteria — download UHC's current Yescarta / CAR-T medical policy and build your submission around its exact language.

## Criteria-Mapping Structure

List every PA criterion from UHC's policy. For each, note the specific document, date, and finding from the chart that satisfies it. Flag any criterion where documentation is incomplete so the treating team can address it before submission — a complete first submission is faster than a denial-and-resubmit cycle.